News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Novacea Cuts IPO Share Price To $6.50 From $11-13
May 9, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Development stage drug maker Novacea Inc. on Tuesday cut its expected initial public offering share price to $6.50 a share from $11 to $13 a share, according to a regulatory filing on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
January 12, 2026
·
3 min read
·
Annalee Armstrong
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Alzheimer’s disease
Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro
January 12, 2026
·
2 min read
·
Tristan Manalac
IPO
Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens
January 12, 2026
·
2 min read
·
Tristan Manalac
